During the past decade, Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (" are "Breast Cancer" (1 trials), "Cancer of Head and Neck" (1 trials), "Cholangiocarcinoma" (1 trials), "Endometrial Neoplasms" (1 trials) and "Esophageal Neoplasms" (1 trials). Many other conditions were trialed in "Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (" in a lesser frequency.

Most popular intervention types in "Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (" are "Drug" (6 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Pembrolizumab" (3 trials), "Carboplatin" (2 trials), "Gemcitabine" (2 trials) and "Lenvatinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (, 5 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".